Ezetimibe in high-risk, previously treated statin patients: a systematic review and network meta-analysis of lipid efficacy

The importance of dyslipidaemia in the pathogenesis of cardiovascular disease in people with diabetes

“…Ezetimibe impairs proximal gut absorption of cholesterol reducing serum LDL‐C on average by one‐fifth . This effect is seen both with ezetimibe monotherapy and when used as adjunctive therapy with a statin and may offer greater reduction of LDL‐C in high risk patients that uptitration of statin dose .…”

“…83 This effect is seen both with ezetimibe monotherapy and when used as adjunctive therapy with a statin and may offer greater reduction of LDL-C in high risk patients that uptitration of statin dose. 83 The Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) study, in which over a quarter of subjects had diabetes, demonstrated that the addition of ezetimibe to statin in the context of a recent acute coronary syndrome reduced LDL-C and this translated through into an absolute reduction in cardiovascular events by 2%. 84 A retrospective cohort study suggests that addition of ezetimibe is associated with a reduction in ischaemic stroke rates in patients with diabetes.…”

“…Ezetimibe impairs proximal gut absorption of cholesterol reducing serum LDL‐C on average by one‐fifth . This effect is seen both with ezetimibe monotherapy and when used as adjunctive therapy with a statin and may offer greater reduction of LDL‐C in high risk patients that uptitration of statin dose . The Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE‐IT) study, in which over a quarter of subjects had diabetes, demonstrated that the addition of ezetimibe to statin in the context of a recent acute coronary syndrome reduced LDL‐C and this translated through into an absolute reduction in cardiovascular events by 2% .…”

Antisense lipoprotein[a] therapy: State-of-the-art and future perspectives

“…Awad et al performed another meta-analysis for exploring the effect of ezetimibe, a drug that inhibits intestinal cholesterol and phytosterol absorption, on Lp[a] concentration [36]. Overall, 7 randomized placebo-controlled clinical trials with 2337 subjects were included in the final analysis, showing that ezetimibe has a modest effect in lowering plasma Lp[a] concentration in hypercholesterolemic subjects (−7.1%; 95% CI, −3.0% to −12.0%), thus reproducing the relatively modest effect already observed on LDL (−13.6%; 95% CI, −6.9% to −20.0%) [37].…”

Low dose of ROSuvastatin in combination with EZEtimibe effectively and permanently reduce low density lipoprotein cholesterol concentration independently of timing of administration (ROSEZE): A randomized, crossover study — preliminary results

“…Several trials demonstrated the superiority of combined treatment of hypercholesterolemia with statins and ezetimibe compared with statin monotherapy, revealing that addition of ezetimibe to statin therapy provides more extensive reduction of LDL-C than doubling the statin dose, and thus allows more patients to achieve the LDL-C goal [14][15][16]. The IMPROVE-IT trial, demonstrated that adding ezetimibe to low intensity statin (simvastatin 40 mg) carries benefit (24% of additional reduction in LDL-C compared with statin monotherapy and lowering the risk of cardiovascular events compared with statin monotherapy with a 2.0-percentage-point lower rate of primary end point defined as a composite of death from cardiovascular disease, a major coronary event or nonfatal stroke [17]) independent of age [18] and sex [19] with a good safety profile, supporting the use of intensive, combined LLT to optimize cardiovascular outcomes [17][18][19].…”